CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Common Shares [Member]	Treasury Shares [Member]	Accumulated Deficit [Member]	Contributed Capital [Member]	Noncontrolling Interest [Member]	Noncontrolling Interest [Member] OncoCyte [Member]	Noncontrolling Interest [Member] ReCyte [Member]	Accumulated Other Comprehensive Income [Member]	Total
BALANCE at Dec. 31, 2008	$ 43,184,606		$ (47,625,392)	$ 93,972	$ 0			$ 0	$ (4,346,814)
BALANCE (in shares) at Dec. 31, 2008	25,076,798
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of subsidiary shares to noncontrolling interest						4,000,000			4,000,000
Common shares issued for new loans and extension of line of credit	304,181								304,181
Common shares issued for new loans and extension of line of credit (in shares)	153,206
Common shares issued for conversion of line of credit and accrued interest	4,134,424								4,134,424
Common shares issued for conversion of line of credit and accrued interest (in shares)	2,493,374
Shares granted for services	229,500								229,500
Shares granted for services (in shares)	135,000
Shares granted for licensing fees	120,000								120,000
Shares granted for licensing fees (in shares)	65,278
Common shares issued for cash	8,000,000								8,000,000
Common shares issued for cash (in shares)	4,400,000
Exercise of options	848,449								848,449
Exercise of options (in shares)	535,832
Warrants exercised	1,616,342								1,616,342
Warrants exercised (in shares)	808,171
Warrants issued for line of credit	398,548								398,548
Warrants issued for services	93,304								93,304
Stock options granted for compensation	488,564								488,564
Beneficial conversion feature	304,400								304,400
NET LOSS			(5,144,499)		590				(5,143,909)
BALANCE at Dec. 31, 2009	59,722,318	0	(52,769,891)	93,972	4,000,590			0	11,046,989
BALANCE (in shares) at Dec. 31, 2009	33,667,659	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of subsidiary shares to noncontrolling interest							2,300,000		2,300,000
Noncontrolling interest in Cell Cure					5,894,255				5,894,255
Common shares issued as part of acquisition of ESI	11,011,864								11,011,864
Common shares issued as part of acquisition of ESI (in shares)	1,383,400
Common shares retired as payment for exercise of options	(249,978)								(249,978)
Common shares retired as payment for exercise of options (in shares)	(40,125)
Exercise of options	855,977								855,977
Exercise of options (in shares)	526,410
Warrants exercised	22,861,458								22,861,458
Warrants exercised (in shares)	12,240,357
Outside investment in subsidiaries					5,894,255				5,894,255
Warrants issued as part of acquisition of ESI	1,778,727								1,778,727
Warrants issued for services	1,979,036								1,979,036
Modification cost of warrants	2,142,202								2,142,202
Stock options granted for compensation	1,033,824								1,033,824
Stock options granted for compensation in subsidiary					61,172				61,172
Foreign currency translation gain								897,338	897,338
NET LOSS			(11,184,618)		(1,002,589)				(12,187,207)
BALANCE at Dec. 31, 2010	101,135,428	0	(63,954,509)	93,972	11,253,428			897,338	49,425,657
BALANCE (in shares) at Dec. 31, 2010	47,777,701	0							47,777,701
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest in Cell Cure					3,213,500				3,213,500
Common shares retired as payment for exercise of options	(28,067)								(28,067)
Common shares retired as payment for exercise of options (in shares)	(6,435)
Exercise of options	251,981								251,981
Exercise of options (in shares)	450,660
Warrants exercised	425,000								425,000
Warrants exercised (in shares)	219,000
Warrants issued as part of merger with Glycosan	954,879								954,879
Outside investment in subsidiaries					3,213,500				3,213,500
Stock options granted for compensation	1,505,566								1,505,566
Stock options granted for compensation in subsidiary					273,635				273,635
Foreign currency translation gain								(1,020,087)	(1,020,087)
NET LOSS			(16,515,500)		(1,928,383)				(18,443,883)
Common shares issued as part of acquisition of CTI assets	2,300,000								2,300,000
Common shares issued as part of acquisition of CTI assets (in shares)	261,959
Common shares issued as part of merger with Glycosan	2,600,000								2,600,000
Common shares issued as part of merger with Glycosan (in shares)	332,903
Treasury shares issued as part of investment in subsidiary	6,000,000	(6,000,000)							0
Treasury shares issued as part of investment in subsidiary (in shares)	1,286,174	(1,286,174)
BALANCE at Dec. 31, 2011	$ 115,144,787	$ (6,000,000)	$ (80,470,009)	$ 93,972	$ 12,812,180			$ (122,749)	$ 41,458,181
BALANCE (in shares) at Dec. 31, 2011	50,321,962	(1,286,174)							49,035,788